Reliability and validity of the Korean version of the University of California–Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Systemic sclerosis (SSc) is associated with a wide range of gastrointestinal (GI) changes. The University of California–Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) instrument is a self-administered GI assessment instrument for patients with SSc. We developed a Korean version of the UCLA SCTC GIT 2.0 instrument and evaluated its reliability and internal consistency. Methods: The participants were 37 Korean patients with SSc. Translation and cross-cultural adaptation of the UCLA SCTC GIT 2.0 were performed according to international standardized guidelines. We evaluated reproducibility by calculating the intraclass correlation coefficients and assessed the internal consistency of the Korean version of the UCLA SCTC GIT 2.0. We assessed its construct validity by evaluating its correlations with the Short Form Health Survey version 2 and EQ-5D scores by means of Spearman correlation analyses. Results: Patients with SSc were mostly women (89.19%) with a mean age of 52.2 years, median disease duration of 24 months, and median modified Rodnan total skin score of 4. The median total GIT score on the UCLA SCTC GIT 2.0 was 0.3. The UCLA SCTC GIT 2.0 Korean version showed excellent internal consistency (Cronbach’s α of total GIT score = 0.863). Most domains of the ULCA SCTC GIT 2.0 were correlated with those of the EuroQol (EQ)-5D score. Conclusions: The Korean version of the UCLA SCTC GIT 2.0 has acceptable internal consistency, reliability, and validity. Therefore, it can be used to assess GIT involvement in Korean patients with SSc.
Abstract
Background/Aims: Systemic sclerosis (SSc) is associated with a wide range of gastrointestinal (GI) changes. The University of California–Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) instrument is a self-administered GI assessment instrument for patients with SSc. We developed a Korean version of the UCLA SCTC GIT 2.0 instrument and evaluated its reliability and internal consistency. Methods: The participants were 37 Korean patients with SSc. Translation and cross-cultural adaptation of the UCLA SCTC GIT 2.0 were performed according to international standardized guidelines. We evaluated reproducibility by calculating the intraclass correlation coefficients and assessed the internal consistency of the Korean version of the UCLA SCTC GIT 2.0. We assessed its construct validity by evaluating its correlations with the Short Form Health Survey version 2 and EQ-5D scores by means of Spearman correlation analyses. Results: Patients with SSc were mostly women (89.19%) with a mean age of 52.2 years, median disease duration of 24 months, and median modified Rodnan total skin score of 4. The median total GIT score on the UCLA SCTC GIT 2.0 was 0.3. The UCLA SCTC GIT 2.0 Korean version showed excellent internal consistency (Cronbach’s α of total GIT score = 0.863). Most domains of the ULCA SCTC GIT 2.0 were correlated with those of the EuroQol (EQ)-5D score. Conclusions: The Korean version of the UCLA SCTC GIT 2.0 has acceptable internal consistency, reliability, and validity. Therefore, it can be used to assess GIT involvement in Korean patients with SSc.
참고문헌 (33)
- Frech TM, "Gastrointestinal and hepatic disease in systemic sclerosis", Rheum Dis Clin North Am, 44, pp.15~28 (2018)
- Kang GW, "Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea : a nationwide population-based study", Br J Dermatol, 178, pp.e37~e39 (2018)
- Denaxas K, "Evaluation and management of esophageal manifestations in systemic sclerosis", Ann Gastroenterol, 31, pp.165~170 (2018)
- Pope J, "Measures of systemic sclerosis (scleroderma):Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler’s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud’s Condition Score (RCS)", Arthritis Care Res (Hoboken), 63(Suppl 11), pp.S98~S111 (2011)
- Khanna D, "Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument", Arthritis Rheum, 61, pp.1257~1263 (2009)
- Baron M, "Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis", J Rheumatol, 38, pp.1925~1930 (2011)
- Bae S, "Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument", Clin Exp Rheumatol, 29(2 Suppl 65), pp.S15~S21 (2011)
- Meijs J, "Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch", Clin Exp Rheumatol, 32(6 Suppl 86), pp.S41~S48 (2014)
- Gorga M, "A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument", Clin Exp Rheumatol, 33(4 Suppl 91), pp.S61~S67 (2015)
- Gualtierotti R, "Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis", Clin Exp Rheumatol, 33(4 Suppl 91), pp.S55~S60 (2015)
- Tas YM, "The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society", Turk J Gastroenterol, 30, pp.234~241 (2019)
- Low AHL, "Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort", Clin Rheumatol, 36, pp.1643~1648 (2017)
- Marighela TF, "Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis : a randomized placebo-controlled trial", Rheumatology (Oxford), 58, pp.1985~1990 (2019)
- Kang JY, "Systematic review : geographical and ethnic differences in gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 20, pp.705~717 (2004)
- 정혜경, "Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Review", Journal of Neurogastroenterology and Motility (JNM), 17(1), pp.14~27 (2011), 대한소화기 기능성질환∙운동학회
- Al-Sheikh H, "Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality", J Rheumatol, 46, pp.1103~1108 (2019)
- Van den Hoogen F, "2013 Classification criteria for systemic sclerosis : an American College of Rheumatology", European League against Rheumatism collaborative initiative, 2013, pp.65, 2737~2747
- LeRoy EC, "Scleroderma(systemic sclerosis) : classification, subsets and pathogenesis", J Rheumatol, 15, pp.202~205 (1988)
- Shreiner AB, "Gastrointestinal manifestations of systemic sclerosis", J Scleroderma Relat Disord, 1, pp.247~256 (2016)
- Mouthon L, "Scleroderma renal crisis : a rare but severe complication of systemic sclerosis", Clin Rev Allergy Immunol, 40, pp.84~91 (2011)
- Condon DF, , The 6th World Symposium on Pulmonary Hypertension:what’s old is new (2019)
- Beaton DE, "Guidelines for the process of cross-cultural adaptation of self-report measures", Spine (Phila Pa 1976), 25, pp.3186~3191 (2000)
- Arredondo EM, "Cultural adaptation of physical activity self-report instruments", J Phys Act Health, 9(Suppl 1), pp.S37~S43 (2012)
- Brazier JE, "Validating the SF-36 health survey questionnaire : new outcome measure for primary care", BMJ, 305, pp.160~164 (1992)
- Testa MA, "Assessment of quality-of-life outcomes", N Engl J Med, 334, pp.835~840 (1996)
- Kim MH, "Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases", Qual Life Res, 14, pp.1401~1406 (2005)
- Carlson DA, "Loss of peristaltic reserve, determined by multiple rapid swallows, is the most frequent esophageal motility abnormality in patients with systemic sclerosis", Clin Gastroenterol Hepatol, 14, pp.1502~1506 (2016)
- McMahan ZH, "Longitudin al assessment of patient-reported outcome measures in systemic sclerosis patients with gastroesophageal reflux disease : Scleroderma Clinical Trials Consortium", J Rheumatol, 46, pp.78~84 (2019)
- Frech TM, "Understanding empirical therapeutics in systemic sclerosis gastrointestinal tract disease", Rheumatology (Oxford), 56, pp.176~177 (2017)
- Ross L, "Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?", Arthritis Care Res (Hoboken), 72, pp.1459~1465 (2020)
- Khanna D, "Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument", Arthritis Rheum, 57, pp.1280~1286 (2007)
- Liu X, "Prevalence and clinical importance of gastroesophageal reflux in Chinese patients with systemic sclerosis", Clin Exp Rheumatol, 30(2 Suppl 71), pp.S60~S66 (2012)
- Spechler SJ, "Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 16, pp.1795~1800 (2002)